Global Intravenous (IV) Fluid Bags Market 2026 – 2035

The intravenous (IV) fluid bags market in the world is estimated to reach USD 3.01 billion in 2026 and is projected to grow at a CAGR of 6.8% between 2026 and 2035 to a size of around USD 5.46 billion. The market growth is a result of the rising incidence of chronic diseases in the world, the increase in surgical operations, the rising geriatric population that needs long-term medical services, the growth in the number of home healthcare and ambulatory care providers, and the rise in technology in the IV fluid packaging and delivery systems.

Market Highlight

• To grasp the market share in the year 2025, the North American market had a share of 42% in the intravenous (IV) fluid bags market.

• Asia Pacific has been projected to grow at a CAGR of 7.8% from 2026 to 2035.

• By type of material, the PVC bags segment took 46% of the market share in 2025.

• By type of material, the segment of the non-PVC bags is increasing the most with a CAGR of 8.5% between 2026 and 2035.

• By type of bag, the single chamber bag segment had the highest market share of 58% in 2025, whereas the multi-chamber bag segment was projected to have the highest CAGR of 9.2% within the projected years between 2026 and 2035.

• By end-user, the hospitals segment grabbed the market share of 64% in 2025.

• IV bags Flexible plastic IV bags currently occupied 78.4% of the primary IV containers market in 2024.

Significant Growth Factors

The Intravenous (IV) Fluid Bags Market Trends present significant growth opportunities due to several factors:

• Surging Chronic Disease Prevalence and Healthcare Burden Globally

The main force behind the IV fluid bags market is the increasing prevalence of chronic diseases such as diabetes, cancer, cardiovascular disorders, and kidney diseases around the world that necessitate extensive use of intravenous therapy in terms of hydration, medication delivery, and nutritional support which the IV bags effectively offer to achieve the best patient outcomes. The World Health Organization indicates that the prevalence of diabetes in the world has increased more than 2 times since 1990, with more than 830 million individuals having the disease nowadays as compared to 7% in 1990, and this constitutes an increase of more than 14% of the world population.

The burden has grown most significantly in the low and middle-income nations where the healthcare facilities are growing at a very fast rate in order to treat the patients. Diabetic patients are also prone to the occurrence of complications such as diabetic ketoacidosis and severe dehydration that necessitate rapid IV fluid replacement, which places a significant amount of strain on sterile intravenous solutions. In cancer care, IV therapy plays various important roles such as in hydration, administration of chemotherapy drugs, anti-nausea drugs, and nutritional support particularly since cancer patients usually have poor oral intake owing to side effects of treatment. The American Cancer Society has estimated that 1,958,310 new cancer cases will be diagnosed in the United States in 2023, versus 1,918,030 cases in 2022, and they are seen as the consistent growth trend.

The cardiovascular diseases such as hypertension and heart failure need close monitoring of fluid by use of IVs, whereas patients that have chronic kidney disease depend on dialysis and parenteral nutrition that requires a lot of IV fluid support over a prolonged treatment period. Aging population in the globe is characterized by much higher dehydration, malnutrition, and multimorbidity, which creates enormous needs of intravenous support in various clinical situations. IV fluid bags are vital medical equipment that is used to administer fluids, medication, electrolytes, and nutrients directly into the bloodstream of a patient using intravenous therapy, they offer answers to controlled and effective methods of administering important substances to patients who are dehydrated, under surgery, being treated due to chronic conditions or in critical care units.

IV bags are available in different sizes, from 50 ml to more than 2,000 ml, depending on the fluid needs of the patient and they are made of medical grade materials such as polyvinyl chloride (PVC), polyolefin, ethylene vinyl acetate (EVA), and polypropylene that make them flexible, sterile and compatible with the different pharmaceutical formulations. Use of IV therapy can be seen across hospitals, emergency rooms, outpatient clinics, ambulatory surgical centres, and more often even at home healthcare setups, according to the data on healthcare utilization so as to make sure that there is hydration, equilibrium of electrolytes, and delivery of medications among other physiological stability in the course of treatment. Procedures performed on the market are estimated at about 310 million procedures annually across the world, and a large share of them require the use of IV fluids during surgeries and post-surgery recovery and the use of IV fluids has created a long-term base business as people need the fluids to recover and to prevent dehydration during the surgical procedures.

• Exponential Growth in Surgical Procedures and Trauma Care Requirements

The market has been experiencing massive growth owing to the rising surgical operations in the world and the rising cases of trauma care that demand intravenous fluids which IV bags are better placed to administer with better sterility, transportability and convenience. Medical research findings also indicate that the world is doing about 310 million surgical operations every year, and about 7 million patients are reported to develop serious perioperative morbidity that needs IV fluids to manage it intensively. Proper hydration during and after operation is extremely important where IV fluids play a vital role in maintaining blood volume, electrolyte balance, and proper hydration during the surgery particularly in the long or complicated surgeries. Patients are often in need of hydration before the surgery to have the perfect physiological parameters, and the postoperative stages often require the further maintenance of the level of IV nutrition and fluid intake, which places the pressure on the specialized IV bag configurations significantly. The increased number of elective procedures all over the globe due to technological progress and the introduction of better surgical methods imposes more demands on IV fluids, and minimally invasive surgery often requires elaborate use of fluids despite less tissue trauma.

The cosmetic surgery industry is a case in point and study of surgical growth, as about 38 million cosmetic surgery events were undertaken across the world in 2024, which is an increase of 42.5% over a period of four years and 17.4 million of these surgical operations involved the use of IV fluids. Emergency medicine and trauma care are highly sensitive market segments as accidents, injuries, and acute medical emergencies will need urgent fluid administration to prevent shock, sustained perfusion of vital organs, and patient stabilization before definitive care can be given. Surge demands of IV fluid bags are formed by natural disasters, car accidents, and mass casualty events, and emergency response measures must focus on timely intravenous access and fluid resuscitation as the main additive measures to save lives. Surgical facilities today find the use of IV bags as an administration method of antibiotic prophylaxis, pain management drugs, and intravenous blood products to be used during surgical operations beyond simple hydration. Hospital admissions data reveal that surgery operations usually use 2-4 bags of IV per operation based on the length of stay and the level of difficulty, and intensive care unit patients normally use 6-8 bags a day during periods of severe illness, and this is a significant amount of per-patient consumption that results in market volumes.

What are the Major Advances Changing the Intravenous (IV) Fluid Bags Market Today?

• Non-PVC Materials and DEHP-Free Formulations:

The most radical technological change is the invention of non-PVC IV bags such as polyolefin, ethylene vinyl acetate (EVA), and polypropylene, which overcomes the health concerns regarding the leaching out of the plasticizers in the traditional PVC bags, and it also provides better biocompatibility and a lower environmental impact, as well as better drug compatibility. Classical PVC IV bags have di(2-ethylhexyl) phthalate (DEHP) as plasticizers to obtain the required flexibility, although studies have expressed concerns over the migration of DEHP into IV fluids especially in vulnerable groups such as neonates, pregnant women, and patients using lipid-based drugs or blood products. Toxicological investigations have shown that DEHP may leak out of PVC containers into intravenous fluids and that lipophilic drugs and solutions are most likely to migrate, resulting in the development of disruption of development, reproduction, and endocrine in sensitive patients.

The non-PVC IV bag market will have a 2025 USD of USD 1.76 billion and is expected to climb to a higher level of USD 3.98 billion in 2035 with a 2025-2035 growth of 8.5% CAGR which reflects faster adoption due to safety issues and regulatory forces. Recent non-PVC substances do not need plasticizers as they are inherently flexible and are able to provide DEHP-free alternatives without additives, which might migrate into pharmaceutical solutions to achieve the required mechanical properties. EVA has become the material of choice and has been shown to be more flexible and clearer enough to be visually examined and compatible with a very wide range of drugs. As per materials analysis, EVA has lower leachability than PVC, has sufficient impact strength to handle and ship, and has good barrier properties to resist the infiltration of oxygen and moisture that may affect the stability of the solution.

The case of Helapet and its innovation of a new line of EVA Infusion Bags in March 2025, which is the safe intravenous delivery and storage of fluids and pharmacological agents in three volume capacities (250ml to 1000ml), can be seen as an example of innovation path, as it is a practical product designed to meet diverse medicinal uses. The healthcare facilities are gradually by defining non-PVC bags as a patient population that can be placed at risk; neonatal intensive care units, oncology departments, and organ transplant programs favor the use of DEHP-free solutions to avoid the risks of potential toxicity as much as possible. Environmental sustainability also becomes another reason behind non-PVC use since both polyolefin and EVA are easier to recycle than PVC and can support waste minimization targets of the healthcare system and sustainability promises of companies in line with the principles of a circular economy.

• Multi-Chamber and Ready-to-Use (RTU) IV Bag Systems:

With multi-chamber IV bags having separate chambers that can hold different fluids or medications that mix as soon as a patient receives the treatment, there has been a significant innovation in this area to meet the need of healthcare efficiency, sterility assurance, and patient safety. Conventional IV therapy frequently involves manual mixing of base solutions with additives such as electrolytes, vitamins or medications in pharmacy departments or at bedside, which poses contamination risks, preparation time and possible medication errors. Multi-chamber IV bags use physical barriers between incompatible components until activated so that healthcare professionals can rapidly prepare patient-specific solutions in sterile, controlled environments especially in intensive care units, emergency departments, and where resources are limited.

The pharmaceutical technology analysis indicates that multi-chamber designs are normally two or three compartments with amino acids, glucose and lipid emulsions to provide parenteral nutrition, or base electrolyte solutions devoid of calcium and phosphate to prevent precipitation. The mechanism of activation includes the use of external forces to tear down barrier seals after which controlled mixing can be done right before administration without compromising sterility in the process. Multi-chamber bags are undergoing a period of rapid adoption with a projected CAGR of 9.2% during 2026 to 2035, featuring benefits such as less time spent on preparation due to a reduced time per bag of 15-20 minutes of time saved compared to manual compounding, a lack of contamination risks due to the multiple handling operations, fewer medication errors because of already pre-formulated solutions, and a longer shelf life due to the separation of the components to prevent degradation. Ready-to-use IV bags are a parallel innovation, which means ready-to-use, pre-mixed and sterilized solutions in final administration form that are not restricted by any preparation requirements and can be used immediately by patients, which is highly advantageous in the emergency scenario in particular.

The RTU bags are selling well in the market with the adoption of workflow efficiency and patient safety by the healthcare systems, the standard formulations simplify inventory but maintain therapeutic conservation. Current RTU devices also implement barcode identification and thus can support closed-loop medication administration systems in which the administration of medication, dose, and patient are validated prior to administration. The multi-chamber segment also has the advantage of parenteral nutrition applications in which complex nutritional regimens need to be combined with amino acids, carbohydrates, lipids, electrolytes, vitamins, and trace elements that traditionally have necessitated complex compounding processes.

• Smart IV Bags with Integrated Sensors and RFID Technology

Sensors, RFID tags, and digital monitoring options in IV bags are the latest innovations in technology that could track in real-time, automatically monitor inventory, and provide a high level of patient safety due to the use of the electronic verification system. The standard methods of IV bag management are based on manual checking, visual inspection, and paper-based documentation, which provide chances to make medication errors, use expired products, and have inefficiency in the supply chain. Smart IV bag technologies contain passive or active RFID tags that encode product data, such as medication type, concentration, lot number, expiration date, and manufacturing information and are scanned automatically at several stages of hospital work. RFID-enabled IV bags as illustrated in the healthcare technology implementations will communicate with the hospital's information system that will ensure automated documentation when the bags are out of storage, at the pharmacy point of verification, and finally at the bedside point of administration to the patient. Advanced smart bags have either printed sensors or embedded electronics monitoring solution temperature to detect possible freezing or overheating in transit and storage that may affect drug stability or efficacy. Next-generation designs have flow sensors or weight measurement systems that can be wirelessly linked to infusion pumps to automatically adjust the flow rate and to put clinicians on notice when bags are almost empty and need to be replaced.

The smart IV bag category supports the issue of medication safety, as the research reveals that IV medication errors happen in 49-90% of the observed medication deliveries, mostly in either incorrect drug, incorrect dosage, or incorrect patient conditions that could be avoided with electronic checking. Barcode and RFID systems facilitate the five rights verification of the right patient, right medication, right dose, right route, and right time before administration which helped eliminate adverse drug events to a great extent. RFID technology has helped in inventory management to provide automated stock level management, first in first out rotation that will make sure that the freshest products are utilized first, expiration dates, prevention of administration of outdated products and recall management that can make sure that the affected lots are identified and removed as fast as possible.

• Sustainable and Recyclable IV Bag Materials

Recent focus on the sustainability of the environment and the minimization of medical waste has seen the creation of materials and recyclable IV bags, as well as the introduction of closed-loop recycling systems to combat the large volumes of plastic waste produced in healthcare. Healthcare facilities in the global context produce tremendous amounts of plastic waste with the IV bags comprising of a large portion of this volume that is usually discarded by either burning or landfills because of contamination issues and the inexistence of recycling facilities. As it has been shown in the environmental research, in the United States alone, hospitals dispose of some 7,000 tons of waste every day, and single-use plastics, such as IV bags, make up a significant portion of that waste. Medical plastics have heightened attention on the environmental aspec; thus, there is ae need to consider sustainable alternatives, lifecycle analysis, and principles of a circular economy, which may be applied to healthcare environments. Contemporary recyclable IV bags come in mono-material designs, which are easier to recycle in comparison to multi-layer composites, and the polyolefin-based bags have specific benefits in terms ofrecyclabilityy and still need the required barrier properties and flexibility.

The recycling process is based on collecting used IV bags in healthcare facilities, cleaningand sterilizing them,, thenrecycling themg mechanically, which turns plastic to pellets, andproducingf new non-medical plastic products that involves creating circular material flows. Issues are regulatory barriers so that recycled medical plastics cannot be reused in new medical equipment, contaminantmanagement sot that thereares no residual pharmaceuticals left after the preparation of the products and economic consideration that recycling infrastructure should have enough volumes to warrant the investment. Bio-based and biodegradable IV bag materials are the new research frontier where renewable resource based materials such ascornstarchh or sugarcane may have end-of-life benefits ofcomposting butt are currently experiencing performance and regulatory approval limitations. The need to focus on sustainable procurement is becoming a priority in healthcare institutions, where environmental considerations have taken over in purchasing strategies that use products with lower environmental impacts, recyclable materials, andmanufacturers thatt have corporate sustainability pledges.

Category Wise Insights

By Material Type

Why PVC Bags Lead the Market?

The biggest segment will be the use of PVC-based IV bags which will occupy a market share of about 46% in the year 2025. Such dominance is an indication of PVC that has a long history of clinical track record, economical usage, superior barrier properties, and manufacturing facilities that supply chains worldwide. Polyvinyl chloride according to materialanalysis, has been used in, medical IV bagsforl more than 50 year, givingg it a long history of safety and performance data over billions of administrations worldwide. PVC IV bags are composed of flexible plastic films that have a combination of PVC resin and plasticizers (traditionally DEHP) to give thefilme the required flexibility, clarity to be seen visually, and durability to handle and transport. These bags offer superior oxygen and moisture barrier properties that eliminate contamination and preserve the solution sterility overa longg shelf life which is a characteristic of between 12-24 months.

The fastest growing one is that of non-PVC bags with a projected CAGR of 8.5% between 2026 and 2035, as a result of health issues around the leaching of plasticizers, the emphasis on environmental sustainability, and the pressure of regulations that favor non-PVC bags. Alternatives such as polyolefin, EVA, and polypropylene do not need plasticizers, and as inherently flexible materials, these materials have great drug compatibility, a factor that reduces environmental impact. The non-PVC IV bags market is expected to reach USD 1.76 billion in 2025 and it is projected to reach above USD 3.98 billion in 2035 due to the high market transition to high-quality materials that uphold patient safety and sustainability.

By Chamber Type

Why Single-Chamber Bags Dominate Applications?

The prevalent segment is single-chamber IV bags that will take about 58% of the total market share in 2025. The applicability of the single-chamber designs to a variety of clinical situations such as hydration therapy, electrolyte replacement, blood product transfusion, and simple medication administration is inherent in this leadership. The products come in single-chamber bags with already prepared ready-to-use solutions in sterile bottles so that the patient can be administered to immediately without the need to prepare solutions.

The category includes saline solutions (0.9% sodium chloride), dextrose solutions (5%, 10%), lactated Ringer's solution, and a variety of electrolyte mixtures that meet the usual clinical requirements. It has been reported that single-chamber bags depending on the hospital utilization data comprise 70-80% of all IV fluid consumption due to their simplicity, instant availability, and suitability to routine use such as surgical fluid replacement, emergency dehydration therapy and medication dilution vehicles.

Multi-chamber bags are growing at the quickest rate with the forecast CAGR of 9.2% between 2026 and 2035, because of parenteral nutrition usage, focus on medication safety, and efficiency of workflow programs. Multi-chamber bags have separated chambers containing incompatible constituents that combine as soon as the bag is administered, especially in total parenteral nutrition(TPN),) where amino acids,glucose,e and lipid emulsions should not be mixed as they precipitate and are damaged. Nutritional support practices indicate that TPN administration is rising around theworld,d with an estimated more than 250,000 patients taking home TPN every year in the United States alone and posing a significant demand on convenient multi-chamber formulations.

By Application

Why Fluid Therapy Dominates IV Bag Applications?

The largest end-user segment is hospital, whicht will take about64% of the% market share in 2025. Such hegemony is a manifestation of the role of hospitals as the major acute care providers of the highest-acuity patients in need of intensive IV care in the context of surgical, medical, and critical care services. The hospital segment encompassesboth generall acute care hospitals, specialty hospitals (cancer centers, cardiachospitals, and, pediatric hospitals), teaching hospitals that are associated with medical schools, and critical access hospitals that cover the rural populations. The healthcare utilization statistics show that hospitals pay very high per-patient ratesforf IV bagscompared ton the other settings because of IV bags used in surgical procedures, intensive careunits,, emergencydepartments,, and complicated medical conditions that need long courses of IV therapy.

Home healthcare is a booming end-user sector due to both containment efforts in healthcare costs and the desire of patients to stay at home and take IV therapy due to the technology that allows this safe procedure. Home IV therapy includes antibiotic medication treatment of chronic infections, parenteral nutrition of patients who cannot consume food, hydration therapy of chronicdiseases, and, palliative care drug administration.

By End-User

Why Hospitals Dominate the Market?

The largest end-user segment is hospitals, which will consume around 64% of the market share in 2025. This hegemony portrays the position of the hospitals as the primary acute care providers that administer to the highest acuity patients who need intensive IV care in surgical, medical, and critical care services. The hospital segment comprises general acute care hospitals, specialty hospitals (cancer facilities, cardiac facilities, and pediatric facilities), teaching hospitals based on medical schools, and critical access hospitals in rural areas. Based on the data of the healthcare utilization, IV bags are used in hospitals much more per patient than in other settings, which is attributed to the volume of surgical procedures, the work of the intensive care unit, the number of patients in the ED, and the presence of complicated medical conditions with long courses of IV treatment.

Home healthcare is the most rapidly growing segment of end-users as a result of the healthcare cost containment efforts, the preference of home care bypatients,s and technological improvements that have made it possible to administer IV therapies safely at home. Home IV therapy involves the use of antibiotics to treat chronic infections, parenteral nutritionforo patients who cannot eat, hydration therapy to treat chronicillnesses,s and palliative car/deliveringg medication.

Report Scope

Regional Analysis

How Big is the North America Market Size?

The North America intravenous (IV) fluid bags market size is estimated at USD 1.18 billion in 2025 and is projected to reach approximately USD 1.92 billion by 2035, with a 6.3% CAGR from 2026 to 2035.

Why did North America Dominate the Market in 2025?

North America is the major player in the world, with their market share estimated to reach about 42% in 2025, due to developed healthcare systems, large volumes of surgery procedures, well-developed emergency medical facilities, well-established insurancecoverager to help with hospital care, and a well-established home healthcare sector. The area is also enjoying a state-of-the-art hospital system, efficient pharmaceutical production, mature supply chain that has made products available, and high healthcare spending that has promoted the use of high-quality products. The US dominated the market with a commanding share owing to its status as the largest healthcare market in the world, with about 6,100 hospitals, 33 million hospital admissions per year, and more than half a million surgeries, which result in massive IV fluid consumption.

The North American market is also defined by high regulatory controls by FDA which guarantees safety and good quality of products, usage of non-PVC materials due to the interests of patient safety,hospitalizationn automation of pharmacies, and the development of complex inventory controls. Large academic medical Centers such as Mayo Clinic, Cleveland Clinic, Johns HopkinsHospital,l and Massachusetts General Hospital are the leaders in terms of clinical innovation and set best practices in IV therapy thataffects national standards. Clinical guidelines, continuingeducation,n and standardization of evidence-based IV therapy practices are promoted by professional associations such asthe Americann Society of Health-System Pharmacists andthe Infusionn Nurses Society.

United States Market Trends

The United States boasts of the largest IV fluid bag market in the world due to the fact that it has theworld'sd highest expenditure on health care at USD 4.5 trillion annually, the largest hospital chain in the world with more than 900000 staffed beds, the most advanced emergency medical services as it answers up to 37 million emergency calls per year, and the most developing home infusion therapy market with over 3 million patients each year. Healthcare statistics show that in the United States there are about 33 million hospital stays every year and the average length of stay is about 5 days, which provides continuous demandforf IV fluids. Its surgical volume consists of more than 50 million operations every year in cardiovascular surgery, orthopedics, general surgery, and the minimally invasiveoperation,n all of which need IV fluid support.

Why is Europe Experiencing Steady Growth?

Europe is undergoing gradual growth and has a growth forecast of 6.5% between 2026 and 2035, characterized by mature healthcare systems, universal healthcare coverage, a greatt focus on patient safety which is a driving force to non-PVC use, and full pharmaceutical regulations. The European market is large, which is a representation of advanced hospital care, well-developed home healthcare systems, stringent medical device regulations via CE marking, and an increasing elderly population in need of long term medical care. Europe also enjoys a big share of the global market, where Germany, France, the United Kingdom, Italy, and Spain are the biggest single markets.

Germany Market Trends

The European market is dominated by Germany because of the developed healthcare system that is universal, about 1,900 hospitals with 500,000 beds,a robustt pharmaceutical manufacturing facility,a focuss on quality and safety leading tothe adoptionn of premiumproducts,s and well-established home healthcare. The German hospitals have excellent clinical standards, advanced pharmacyfunctions,s and complete IV therapyregimenss that facilitate extensive use of products. The market is also sustainable and has been focusing on recyclable andenvironmentally friendlyy IVbags,s as the market demand is ever growing in line with the national environmental objectives.

Why is Asia Pacific Experiencing Rapid Growth?

The Asia Pacific region is one such region that is rapidly growing with the forecast of 7.8% CAGR between theyearsr 2026 and 2035 due to the high population, increasing population, growing healthcare infrastructure, rising healthcare spending, increasing surgical volumes, and increasing chronic disease prevalence. The area also enjoys the demographic factors such as urbanization that generates healthcare needs, increased middle classes that can afford hospital services, and older populations that require massive healthcare services. China and India are some of the most dynamic markets that have a huge population, government healthcare investment infrastructures, and modernizing hospital systems at a rapid pace.

China Market Trends

China has the highest rate of IV fluid bags in Asia Pacific andthe bestt market due to the largest population of 1.4 billion people in the world, the largest network of hospitals having more than 35,000 hospitals, healthcare reforms are under way by thegovernment,t which is expanding insurancecoverage,, increasing surgical volumes of more than 60 million surgeries per annum and domestic production capacity. Based on the Chinese healthcare statistics, the number of hospital admissions is above 260 million annually withan upwardd growth index. The Healthy China 2030 initiative of the Chinese government focuses on the accessibility to healthcare, qualityimprovement,t and development of infrastructure that promotes growth in the market. The domestic producers such as Shandong Pharmaceutical Glass and ShandongWeigao,o are capable of producing large volumes of IV bags to cater to the domestic market but with rising export volumes to the international markets.

Top Players in the Market

• Baxter International Inc. 

• B. Braun Melsungen AG 

• Fresenius Kabi AG 

• ICU Medical Inc. 

• Pfizer Inc. 

• Grifols S.A. 

• JW Life Science Corporation 

• Technoflex 

• Sippex IV Bag 

• Renolit SE 

• Others

Key Developments

The market has undergone significant developments as industry participants seek to expand capabilities and enhance product portfolios.

• In April 2025: Helapet introduced another new product, the EVA infusion bags, which are safe to use in intravenous delivery and storage of fluids and medications. The bags can be bought in three sizes, 250 ml, 500ml,l and 1000ml,l and can be usedforn a variety of medical purposes, and it is an industry innovation that the bags use non-PVC materials.

• In February 2024: A 1000 ml injection was launched by B. Braun Medical Inc. of 2,000 units heparin sodium in 0.9% sodium chloride. The product comes in containers of EXCEL IV which does not incorporate the use of PVC, DEHP or natural rubber latex material, as part of thecompany'sy efforts to establish safer material and in respect to patient and environmental safety.

These strategic activities have allowed companies to strengthen market positions, expand product offerings, enhance technological capabilities, and capitalize on growth opportunities within the expanding market.

The Intravenous (IV) Fluid Bags Market is segmented as follows:

By Material Type

• PVC Bags

o   DEHP-containing PVC

o   DEHP-free PVC

• Non-PVC Bags

o   Polyolefin Bags

o   EVA Bags

o   Polypropylene Bags

• Glass Bottles

By Chamber Type

• Single-Chamber Bags

• Multi-Chamber Bags

o   Two-Chamber Bags

o   Three-Chamber Bags

By Capacity

• 50-100 ml

• 100-250 ml

• 250-500 ml

• 500-1000 ml

• Above 1000 ml

By Application

• Fluid Therapy

o   Hydration

o   Electrolyte Balance

• Nutrition Therapy

o   Parenteral Nutrition

o   Total Parenteral Nutrition (TPN)

• Drug Administration

o   Antibiotics

o   Chemotherapy

o   Pain Management

• Blood & Blood Products

• Other Applications

By End-User

• Hospitals

o   General Hospitals

o   Specialty Hospitals

• Ambulatory Surgical Centers

• Home Healthcare

• Clinics

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America